Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab vs Chemotherapy with Radiotherapy for Esophageal Cancer
NCT02858206Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2016
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02858206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858206.